Performance of the thrombolysis in myocardial infarction ST elevation myocardial infarction risk score in elderly patients  by Rathore, Saif S. et al.
180A ABSTRACTS - Cardiac Function and Heart Failure JACC March 19,2003 
1112-86 Performance of the Thrombolysis in Myocardial 
infarction ST Elevation Myocardial Infarction Risk Score 
in Elderly Patients 
Saif S. Rathora, Kevin P. Weinfurt, JoAnne M. Foody, Harlan M. Krumholz, Yale 
University School of Medicine, New Haven, CT, Qualidigm, Middletown. CT 
Background: The Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial 
infarction (STEMI) mortalitv risk score was developed in a randomized trial copulation: its ~ 
accuracy in community-based elderly STEMI patients is unknown. 
Methods: The Coooerative Cardiovascular Proiect iCCPI database was used to deter- 
I  I  
mine the prognostic performance of the TIMI score in patients age 65 years and older 
hospitalized with confirmed STEMI in 1994-96 (n=47,682). Accuracy of admission TIMI 
scores (range 2-14. lower scores indicate less risk) was assessed by determining cali- 
bration (visual inspection of calibration plots and Hosmer-Lemeshow goodness of fit (gof) 
test, p<O.O5 indicates poor fit) and discrimination (c-statistic, ~~0.50 for no discrimination, 
c=l .OO for perfect discrimination) from a logistic regression model for 30-day mortality. 
Differences in TIMI soora performance bePween patients who did and did not receive 
acute reperfusion therapy (RT) were tested using a TIMI score x RT interaction term. 
Thirty-day mortality rates in CCP were compared with published TIMI score rates. 
Results: The median TIMI score was 6 (25th.75th percentile 4.6) and the 30-day mortal- 
ity rate was 20.1%. Mortality rates were higher among patients with higher TIMI scores 
(TIMI score 2: 4.4% vs. TIMI score >6: 35.6%. p<O.OOl for trend), but the TIMI score pro- 
vided only modest discrimination (c=O.67) and poor calibration (gof p<O.OOOl). TIMI 
score accuracy varied by use of RT (pcO.001 for TIMI score x RT interaction) as calibra- 
tion (gof p=O.O31) and discrimination (c=O.69) Were better among patients who received 
RT than patients who did not receive RT (gof p<O.OOl. c=O.63). TIMI score 30-day mor- 
tality rates in CCP were higher than published TIMI estimates (PcO.001, e.g., TIMI score 
2: 4.4% CCP vs. 2.2% published rate). 
Conclusion: The TIMI score provides only modest prognostic discrimination and calibra- 
tion among elderly patients hospitalized with STEMI, particularly those who do not 
receive RT. Published TIMI 30-day mortality rates underestimated actual 30.day mortal- 
ity rates. Our findings highlight the limitations of applying randomized trial-derived risk 
scores to community populations. 
1112-87 Differences Between TIME (Trial of Invasive Versus 
Medical Therapy in Elderly Patients With Chronic 
Angina) and Registry Patients, and Impact on Outcome 
Matthias E. Pfisterer, Stefan Wyrsch, Gabriela Kuster, Lukas Schdb, Leticia Grize, 
Raban V. Jeger, Christoph Kaiser, Peter T. Buser, The TIME Investigators, University 
Hospital Basal, Basel. Switzerland 
Background: In trial settings, patients selected for studies often are less sick than regis- 
try patients making study results not generalizable. In the TIME study (Trial of Invasive 
vs. Medical Therapy in the Elderly with chronic angina), patients 275 years of age were 
included based on clinical presentation (angina CCS (Canadian Cardiac Society) class 2 
II despite 2 2 drugs) and not based on coronary anatomy. 
Methods: To assess whether these inclusion criteria led to a different patient population 
than usually referred for invasive management, all 166 TIME patients of 4 hospitals (62% 
of TIME) were compared at baseline with all 201 patients of the same hospitals referred 
for coronary angiography during the study period with TIME inclusion criteria but no con- 
sent (REFER patients). One year outcome regarding major cardiac events (MACE: 
death, infarction (Ml) and hospitalisations for acute disease (ACS) were compared 
between invasive TIME and REFER patients. 
Results: In comparison to REFER patients, TIME patients were older (79+ 3 vs. 76+ 2 
years, p<.OOl). more women (44 vs. 35%. p=.O7), had more angina (class 3.1 vs. 2.3+ 
1.2, pc.OOOl), more antianginal drugs/patient (2.6 vs. 2.1, pc.0001) and somewhat less 
prior revascularisations (20 vs. 26%, p=.O7); however, ejection fraction and distribution of 
vessel disease were similar. Regarding one-year outcome, there were no significant dif- 
ferences between invasive TIME and REFER patients in symptoms, quality of live and 
MACE: rate of death 9.6 vs. 13.6%. death/Ml 14.9 vs. 15.2%, MACE 22.3 VS. 18.7% (all 
p>.4), and this remained not significant after adjustment for baseline differences. 
Conclusions: This analysis shows that coronary disease in patients selected for TIME 
was not less severe than in REFER patients, and TIME patients needed more drugs to 
treat angina which was more severe than in REFER patients. Since outcome events 
were also similar in invasive TIME and REFER patients, reported results of TIME should 
be relevant to most patients of this age group. 
1112-88 Acute and Long-Term Outcomes of Multivessel Stenting 
in Patients Aged 80 Years 
Yoshio Kobavashi. Roxana Mehran, Makoto Hirose, George Dangas, Alexandra J. 
Lansky, Gregg W. Stone, lssam Moussa, Gary S. Mint.& Michael 8. Collins, Edward 
Kreps, Jeffrey W. Moses, Martin B. Leon, Cardiovascular Research Foundation, New 
York. NY 
Background: Multivessel stenting is routinely performed at a single procedure even in 
the very elderly. Clinical outcomes of multivessel stenting in this advanced age group 
have not been fully evaluated. 
Methods: Multivessel stenting was performed in 969 patients with 2,919 lesions. 
Patients were classified into two groups according to age: (1) ~60 years old (894 
patients, 2,676 lesions) and (2) Zt30 years old (75 patients, 241 lesions). 
Results: 
Female (%) 
Diabetes mellitus (%) 
Reference (mm) 
Pre MLD (mm) 
Post MLD (mm) 
Procedure Q-MI (%) 
Proc non-Q Ml (%) 
In-hosp CABG (%) 
In-hosp death (%) 
Angio. sucoess (%) 
Bleeding camp (%) 
Vascular camp (%) 
Neuro. event (%) 
Pulmonary edema (%) 
1 -month MACE (%) 
l-year death (%) 
l-year MI (“/) 
1 -year TLR (%) 
1 -year MACE (%) 
-caramc aeath. Anglo=anglographlC, comp=complaatlon, Neuro=neurological, 
MACE=major adverse cardiac event, MLD=minimum lumen diameter, Proc=procedure, 
TLR=target lesion revascularization. 
Conclusions: Multivessel stenting in pts Z60 yrs of age is associated with increased 
acute and long-term complications. This translates into a higher l-month and l-year 
MACE rate even though the need for repeat revascularization tends to be lower. 
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1135-59 Inhibition of P38 Mitogen-Activated Protein Kinase 
Protects the Heart Against Cardiac Remodeling in Mice 
With Heart Failure Due to Myocardial Infarction 
Yun-He Liu PI Dahai Wang, Nour-Eddine Rhakb. Xiao-Ping Yang, Jiang Xu, AI-Li Yu, Amy 
E. Rudolph, Oscar A. Carretero, Henry Ford Hospital, Detroit, MI, Pharmacia. St. Louis, 
MO 
Background: mitogen-activated protein kinases (MAPKs) have emerged as an impor- 
tant pathophysiological regulator during the development of heart failure. ~36 MAPK 
activity has been shown to be elevated in cardiac hypertrophy and heart failure. We used 
a mouse model of myocardial infarction (Ml) to test the hypotheses that 1) inhibibon of 
p36 MAPK activity may improve cardiac function and myocardial morphology after MI; 
and 2) combined treatment with a p38 MAPK inhibitor and an angiotensin-converting 
enzyme inhibitor (ACEi) provides further cardioprotection. 
Methods Ml was induced in C57BU6J mice by ligating the left anterior descending cor- 
onary artery. Two weeks later, they were treated for 12 weeks with a) vehicle, b) SC-409, 
a pyrazole class of p38 MAPK inhibitor (p38i; 30 mg/kg/day in food), c) ACEi (enalapril; 
20 mg/kg in drinking water) or d) both p38i and ACEi. Echocardiography was performed 
and systolic blood pressure (SBP) measured before Ml and weekly thereafter. At the end 
of the study, interstitial collagen fraction (ICF) and myocyte cross-sectional area (MCSA) 
were examined histologically. 
Results We found that 1) in vehicle-treated mice with heart failure, left ventricular ejec- 
tion fraction (LVEF) and cardiac output (CO) decreased while LV mass, diastolic dimen- 
sion (LVDd), ICF and MCSA all increased significantly; 2) inhibition of p36 MAPK 
sigmficantly improved cardiac function and remodeling, as evidenced by increased LVEF 
(vehicle vs p36i: 20.3 f 1.6 YS 35.4 * 2.2%; p< 0.001) and CO (11.8 * 0.9 vs 19.1 * 1.2 
ml/mln; p < 0.01) and decreased LV mass (177 t 12 vs 106 * 3.4 mg; p < O.OOl), MCSA 
(345 * 10 “s 266 * 5 vm2; p < 0.001) and ICF (12.7 + 0.6 YS 9.8 * 0.4 %; /I < 0.001); and 
3) ACEi and p36i monotherapy each had similar beneficial effects. Combined treatment 
with p36i and ACEi provided only limited added benefit. 
Conclusion: Our data suggest that inhibition of ~38 MAPK provides significant cardio- 
protection in mice with heart failure post-MI. 
1135-60 Simvastatin Restores Contractile Function and 
Reduces Cardiac Remodeling in a Genetic Model of 
Cardiomyopathy 
Juan C. Osorio, Seena S. Abraham, Beth D. Kaufman, Paloma De Prada, Shunichi 
Homma. James K. Liao. Seema Mital. Columbia Universitv. New York. NY, Brigham 8 
Women’s Hospital, Bosion, MA 
Background: 82 kinin receptor (B2R) stimulation activates endothelial nitric oxide syn- 
thase (eNOS). Disruption of the B2R results in dilated cardiomyopathy which may be 
related to decreased NO. Simvastatin (Sim) increases cardiac NO production through 
increased expression and/or phosphorylation of eNOS. We evaluated the ability of Sim to 
upregulate NO production and reduce contractile dysfunction and cardiac remodeling in 
mice lacking the B2R. 
Methods: 2 month old, male mice with genetic disruption of the B2R (BPRKO) (n=16) and 
